AbbVie Already Dividend King? Why Apogee Deal Could Cement a Dynasty
AbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Knowing what to say when negotiating with creditors is essential for success. Equip yourself with effective phrases and strategies.
12,731 articlesAbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
A year-by-year calculation shows how much capital you need to generate $3,000 a month via dividends, with tradeoffs a...
Bitcoin climbs past $64,000 as spot BTC ETF inflows resume, highlighting a price-driven rebound that may outpace inst...
Morgan Stanley’s MSBT, the bank’s first spot Bitcoin ETF, has surged to $233 million in AUM in its first month, under...
A high-profile insider sale at UroGen Pharma raises questions about market signals and biotech risk. This article unp...
Rocket Lab stock surged on upbeat results and new contracts, signaling renewed investor interest. This guide breaks d...
Oil prices march upward again as tensions between the U.S. and Iran flare, pushing Brent above $80 and complicating i...
Microsoft’s 2018 GitHub acquisition is fueling a rapid AI flywheel, elevating Copilot Enterprise and Azure growth. A ...
A geopolitical shock pushes cryptocurrency markets into volatility, with Cardano ADA tumbling toward $0.16 as Kraken ...
A SpaceX IPO could reshape tech investing, but it won’t happen in a vacuum. This guide explains why Amazon’s space an...
California's new EV incentive is tilting the playing field for Rivian and Tesla. With Q1 results out, investors are w...
BlackRock filed with the SEC on May 8 to launch two tokenized money market funds, including a digital class for BSTBL...